FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2054341710> ?p ?o ?g. }

• W2054341710 endingPage "518" @default.
• W2054341710 startingPage "514" @default.
• W2054341710 abstract "Cisplatin-based combination chemotherapy for patients with advanced transitional cell carcinoma (TCC) of the urothelium has limitations, and new therapies need to be evaluated.Ifosfamide 1.0 gm/m2 on Days 1-4 and paclitaxel 135 mg/m2 by 24-hour infusion on Day 4 were administered to 26 patients with locally unresectable or metastatic TCC. Cycles were repeated every 21 days for a maximum of 6 cycles; dose escalation was dependent on whether Grade 3 or 4 toxicities occurred.There were 24 males and 2 females, with a median age of 66 years and a median Eastern Cooperative Oncology Group performance status of 0. The median number of cycles administered was 3. Twelve patients had Grade 3 or 4 hematologic toxicities, including 1 patient who died of a gastrointestinal hemorrhage while pancytopenic. There were no episodes of neutropenic fever. Two patients each had a complete response (CR) that lasted 5 and 28 months, respectively (response rate: 15%; 95% CI: 2-45%), among the 13 patients who had received prior chemotherapy. Of the 13 patients without prior chemotherapy, there were 3 with complete responses and 1 with a partial response ranging from 8 to 25+ months (RR: 30.7%; 95% CI: 9-61%).The combination of ifosfamide and paclitaxel is well tolerated and can produce objective responses in patients who are chemonaïve or have had prior therapy. For previously untreated patients, the addition of ifosfamide does not appear to result in a better response rate than single agent paclitaxel; and for previously treated patients, the addition of paclitaxel does not appear to result in a better response rate than single agent ifosfamide." @default.
• W2054341710 created "2016-06-24" @default.
• W2054341710 creator A5002577080 @default.
• W2054341710 creator A5002909668 @default.
• W2054341710 creator A5033629344 @default.
• W2054341710 creator A5035913183 @default.
• W2054341710 creator A5040850986 @default.
• W2054341710 creator A5047231224 @default.
• W2054341710 creator A5059393603 @default.
• W2054341710 creator A5078996026 @default.
• W2054341710 date "1999-08-01" @default.
• W2054341710 modified "2023-10-15" @default.
• W2054341710 title "A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium" @default.
• W2054341710 cites W1765633821 @default.
• W2054341710 cites W1802318902 @default.
• W2054341710 cites W1820014750 @default.
• W2054341710 cites W1820902945 @default.
• W2054341710 cites W1827428051 @default.
• W2054341710 cites W1862964936 @default.
• W2054341710 cites W1870673602 @default.
• W2054341710 cites W1893740135 @default.
• W2054341710 cites W1936664258 @default.
• W2054341710 cites W1939723756 @default.
• W2054341710 cites W1941332786 @default.
• W2054341710 cites W1957837469 @default.
• W2054341710 cites W1975976475 @default.
• W2054341710 cites W1979992851 @default.
• W2054341710 cites W2008702837 @default.
• W2054341710 cites W2020602349 @default.
• W2054341710 cites W2143656505 @default.
• W2054341710 cites W2338649218 @default.
• W2054341710 doi "https://doi.org/10.1002/(sici)1097-0142(19990801)86:3<514::aid-cncr21>3.0.co;2-9" @default.
• W2054341710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10430261" @default.
• W2054341710 hasPublicationYear "1999" @default.
• W2054341710 type Work @default.
• W2054341710 sameAs 2054341710 @default.
• W2054341710 citedByCount "65" @default.
• W2054341710 countsByYear W20543417102012 @default.
• W2054341710 countsByYear W20543417102013 @default.
• W2054341710 countsByYear W20543417102014 @default.
• W2054341710 countsByYear W20543417102015 @default.
• W2054341710 countsByYear W20543417102016 @default.
• W2054341710 countsByYear W20543417102017 @default.
• W2054341710 countsByYear W20543417102018 @default.
• W2054341710 countsByYear W20543417102020 @default.
• W2054341710 crossrefType "journal-article" @default.
• W2054341710 hasAuthorship W2054341710A5002577080 @default.
• W2054341710 hasAuthorship W2054341710A5002909668 @default.
• W2054341710 hasAuthorship W2054341710A5033629344 @default.
• W2054341710 hasAuthorship W2054341710A5035913183 @default.
• W2054341710 hasAuthorship W2054341710A5040850986 @default.
• W2054341710 hasAuthorship W2054341710A5047231224 @default.
• W2054341710 hasAuthorship W2054341710A5059393603 @default.
• W2054341710 hasAuthorship W2054341710A5078996026 @default.
• W2054341710 hasBestOaLocation W20543417101 @default.
• W2054341710 hasConcept C121332964 @default.
• W2054341710 hasConcept C121608353 @default.
• W2054341710 hasConcept C126322002 @default.
• W2054341710 hasConcept C126894567 @default.
• W2054341710 hasConcept C141071460 @default.
• W2054341710 hasConcept C142424586 @default.
• W2054341710 hasConcept C2776694085 @default.
• W2054341710 hasConcept C2777292972 @default.
• W2054341710 hasConcept C2777506904 @default.
• W2054341710 hasConcept C2777540882 @default.
• W2054341710 hasConcept C2777546739 @default.
• W2054341710 hasConcept C2778065480 @default.
• W2054341710 hasConcept C2778239845 @default.
• W2054341710 hasConcept C2779762690 @default.
• W2054341710 hasConcept C2780352672 @default.
• W2054341710 hasConcept C71924100 @default.
• W2054341710 hasConcept C87355193 @default.
• W2054341710 hasConcept C90924648 @default.
• W2054341710 hasConceptScore W2054341710C121332964 @default.
• W2054341710 hasConceptScore W2054341710C121608353 @default.
• W2054341710 hasConceptScore W2054341710C126322002 @default.
• W2054341710 hasConceptScore W2054341710C126894567 @default.
• W2054341710 hasConceptScore W2054341710C141071460 @default.
• W2054341710 hasConceptScore W2054341710C142424586 @default.
• W2054341710 hasConceptScore W2054341710C2776694085 @default.
• W2054341710 hasConceptScore W2054341710C2777292972 @default.
• W2054341710 hasConceptScore W2054341710C2777506904 @default.
• W2054341710 hasConceptScore W2054341710C2777540882 @default.
• W2054341710 hasConceptScore W2054341710C2777546739 @default.
• W2054341710 hasConceptScore W2054341710C2778065480 @default.
• W2054341710 hasConceptScore W2054341710C2778239845 @default.
• W2054341710 hasConceptScore W2054341710C2779762690 @default.
• W2054341710 hasConceptScore W2054341710C2780352672 @default.
• W2054341710 hasConceptScore W2054341710C71924100 @default.
• W2054341710 hasConceptScore W2054341710C87355193 @default.
• W2054341710 hasConceptScore W2054341710C90924648 @default.
• W2054341710 hasIssue "3" @default.
• W2054341710 hasLocation W20543417101 @default.
• W2054341710 hasLocation W20543417102 @default.
• W2054341710 hasOpenAccess W2054341710 @default.
• W2054341710 hasPrimaryLocation W20543417101 @default.
• W2054341710 hasRelatedWork W1985695765 @default.
• W2054341710 hasRelatedWork W1994109701 @default.

• next